LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Merit Medical Systems Inc

Slēgts

SektorsVeselības aprūpe

81.23 -1.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

79.48

Max

82.18

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.8M

28M

Pārdošana

1.7M

384M

P/E

Sektora vidējais

41.451

121.746

Peļņas marža

7.225

Darbinieki

7,400

EBITDA

-4.4M

80M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+30.31% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 24. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-108M

4.8B

Iepriekšējā atvēršanas cena

82.33

Iepriekšējā slēgšanas cena

81.23

Ziņu noskaņojums

By Acuity

50%

50%

149 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Merit Medical Systems Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. febr. 23:47 UTC

Karstas akcijas

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026. g. 11. febr. 22:59 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Grab Holdings to Buy U.S.-Based Stash Financial

2026. g. 11. febr. 23:54 UTC

Peļņas

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026. g. 11. febr. 23:49 UTC

Peļņas

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026. g. 11. febr. 23:45 UTC

Peļņas

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026. g. 11. febr. 23:42 UTC

Peļņas

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026. g. 11. febr. 23:41 UTC

Peļņas

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026. g. 11. febr. 23:40 UTC

Peļņas

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026. g. 11. febr. 23:35 UTC

Tirgus saruna

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026. g. 11. febr. 23:18 UTC

Tirgus saruna

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026. g. 11. febr. 23:14 UTC

Tirgus saruna

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026. g. 11. febr. 22:58 UTC

Peļņas

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026. g. 11. febr. 22:57 UTC

Peļņas

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026. g. 11. febr. 22:54 UTC

Peļņas

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026. g. 11. febr. 22:53 UTC

Peļņas

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:23 UTC

Peļņas

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026. g. 11. febr. 22:19 UTC

Peļņas

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026. g. 11. febr. 22:16 UTC

Peļņas

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Salīdzinājums

Cenas izmaiņa

Merit Medical Systems Inc Prognoze

Cenas mērķis

By TipRanks

30.31% augšup

Prognoze 12 mēnešiem

Vidējais 105.33 USD  30.31%

Augstākais 122 USD

Zemākais 90 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merit Medical Systems Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

8

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

95.585 / 96.35Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

149 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Merit Medical Systems Inc

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
help-icon Live chat